Century Therapeutics Inc
IPSC0.900USD
+0.137+17.89%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
77.87MMarket Cap
LossP/E TTM
More Details of Century Therapeutics Inc Company
Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.
Century Therapeutics Inc Info
Ticker SymbolIPSC
Company nameCentury Therapeutics Inc
IPO dateJun 17, 2021
CEOPfeiffenberger (Brent)
Number of employees140
Security typeOrdinary Share
Fiscal year-endJun 17
Address25 N 38Th Street, 11Th Floor
CityPHILADELPHIA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19104
Phone12159814000
Websitehttps://www.centurytx.com/
Ticker SymbolIPSC
IPO dateJun 17, 2021
CEOPfeiffenberger (Brent)
Company Executives of Century Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Chad Cowan, Ph.D.
Dr. Chad Cowan, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
987.39K
-0.55%
Dr. Brent Pfeiffenberger, Pharm.D.
Dr. Brent Pfeiffenberger, Pharm.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
639.01K
-68.62%
Mr. Douglas Carr, CPA
Mr. Douglas Carr, CPA
Interim Chief Financial Officer
Interim Chief Financial Officer
392.31K
-0.07%
Dr. Gregory (Greg) Russotti, Ph.D.
Dr. Gregory (Greg) Russotti, Ph.D.
Chief Technology and Manufacturing Officer
Chief Technology and Manufacturing Officer
350.25K
-0.15%
Dr. Han Lee, Ph.D.
Dr. Han Lee, Ph.D.
Independent Director
Independent Director
--
--
Dr. Martin Patrick Murphy, Ph.D.
Dr. Martin Patrick Murphy, Ph.D.
Independent Director
Independent Director
--
--
Dr. Kimberly Lynn Blackwell, M.D.
Dr. Kimberly Lynn Blackwell, M.D.
Independent Director
Independent Director
--
--
Ms. Daphne E. Quimi, CPA
Ms. Daphne E. Quimi, CPA
Independent Director
Independent Director
--
--
Mr. Timothy P. (Tim) Walbert
Mr. Timothy P. (Tim) Walbert
Independent Director
Independent Director
--
--
Dr. Carlo Rizzuto, Ph.D.
Dr. Carlo Rizzuto, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Chad Cowan, Ph.D.
Dr. Chad Cowan, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
987.39K
-0.55%
Dr. Brent Pfeiffenberger, Pharm.D.
Dr. Brent Pfeiffenberger, Pharm.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
639.01K
-68.62%
Mr. Douglas Carr, CPA
Mr. Douglas Carr, CPA
Interim Chief Financial Officer
Interim Chief Financial Officer
392.31K
-0.07%
Dr. Gregory (Greg) Russotti, Ph.D.
Dr. Gregory (Greg) Russotti, Ph.D.
Chief Technology and Manufacturing Officer
Chief Technology and Manufacturing Officer
350.25K
-0.15%
Dr. Han Lee, Ph.D.
Dr. Han Lee, Ph.D.
Independent Director
Independent Director
--
--
Dr. Martin Patrick Murphy, Ph.D.
Dr. Martin Patrick Murphy, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Bayer AG
14.52%
Versant Ventures
13.93%
Fujifilm Holdings Corp
7.97%
Bain Capital Life Sciences Investors, LLC
4.05%
Renaissance Technologies LLC
2.96%
Other
56.57%
Shareholders
Shareholders
Proportion
Bayer AG
14.52%
Versant Ventures
13.93%
Fujifilm Holdings Corp
7.97%
Bain Capital Life Sciences Investors, LLC
4.05%
Renaissance Technologies LLC
2.96%
Other
56.57%
Shareholder Types
Shareholders
Proportion
Corporation
22.48%
Venture Capital
13.97%
Hedge Fund
11.40%
Investment Advisor
10.67%
Individual Investor
3.63%
Investment Advisor/Hedge Fund
2.45%
Research Firm
0.08%
Private Equity
0.03%
Other
35.29%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
172
36.05M
41.73%
-14.24M
2025Q2
185
65.43M
75.94%
-12.74M
2025Q1
190
67.80M
85.48%
-12.38M
2024Q4
199
74.05M
87.09%
-5.74M
2024Q3
197
77.29M
91.61%
-2.73M
2024Q2
195
76.53M
90.84%
+3.21M
2024Q1
192
59.55M
90.31%
-4.03K
2023Q4
185
53.19M
83.25%
-1.66M
2023Q3
177
52.18M
87.54%
-4.25M
2023Q2
185
53.42M
89.72%
-5.97M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Bayer AG
12.68M
14.67%
--
--
Apr 15, 2025
Versant Ventures
12.17M
14.08%
--
--
Apr 15, 2025
Fujifilm Holdings Corp
6.96M
8.05%
--
--
Apr 15, 2025
Bain Capital Life Sciences Investors, LLC
5.41M
6.26%
--
--
Jun 30, 2025
Renaissance Technologies LLC
2.02M
2.34%
+837.18K
+70.63%
Jun 30, 2025
The Vanguard Group, Inc.
2.11M
2.44%
-267.41K
-11.25%
Jun 30, 2025
Two Sigma Investments, LP
951.41K
1.1%
+788.50K
+484.02%
Jun 30, 2025
Dafna Capital Management, LLC
1.70M
1.97%
--
--
Jun 30, 2025
Casdin Capital, LLC
1.23M
1.42%
-1.98M
-61.77%
Jun 30, 2025
Syncona Portfolio Ltd
1.21M
1.4%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ProShares Hedge Replication ETF
0%
ProShares UltraPro Russell2000
0%
Schwab U.S. Small-Cap ETF
0%
Schwab U.S. Broad Market ETF
0%
Proshares Ultra Russell 2000
0%
iShares Micro-Cap ETF
0%
iShares Russell 3000 ETF
0%
Global X Russell 2000 Covered Call ETF
0%
iShares Russell 2000 Value ETF
0%
Dimensional US Core Equity 1 ETF
0%
View more
ProShares Hedge Replication ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Schwab U.S. Small-Cap ETF
Proportion0%
Schwab U.S. Broad Market ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
iShares Micro-Cap ETF
Proportion0%
iShares Russell 3000 ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Century Therapeutics Inc?
The top five shareholders of Century Therapeutics Inc are:
Bayer AG holds 12.68M shares, accounting for 14.67% of the total shares.
Versant Ventures holds 12.17M shares, accounting for 14.08% of the total shares.
Fujifilm Holdings Corp holds 6.96M shares, accounting for 8.05% of the total shares.
Bain Capital Life Sciences Investors, LLC holds 5.41M shares, accounting for 6.26% of the total shares.
Renaissance Technologies LLC holds 2.02M shares, accounting for 2.34% of the total shares.
Bayer AG holds 12.68M shares, accounting for 14.67% of the total shares.
Versant Ventures holds 12.17M shares, accounting for 14.08% of the total shares.
Fujifilm Holdings Corp holds 6.96M shares, accounting for 8.05% of the total shares.
Bain Capital Life Sciences Investors, LLC holds 5.41M shares, accounting for 6.26% of the total shares.
Renaissance Technologies LLC holds 2.02M shares, accounting for 2.34% of the total shares.
What are the top three shareholder types of Century Therapeutics Inc?
The top three shareholder types of Century Therapeutics Inc are:
Bayer AG
Versant Ventures
Fujifilm Holdings Corp
Bayer AG
Versant Ventures
Fujifilm Holdings Corp
How many institutions hold shares of Century Therapeutics Inc (IPSC)?
As of 2025Q3, 172 institutions hold shares of Century Therapeutics Inc, with a combined market value of approximately 36.05M, accounting for 41.73% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -34.21%.
What is the biggest source of revenue for Century Therapeutics Inc?
In --, the -- business generated the highest revenue for Century Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
